Literature DB >> 9704249

Comparative tolerability of drug therapies used to treat incontinence and enuresis.

R G Owens1, M M Karram.   

Abstract

Drug therapy for incontinence and enuresis has met with varying degrees of success. Currently, there is no medication available that specifically targets the lower urinary tract without having untoward effects elsewhere in the body. Patients with urge incontinence are the most difficult group to treat. The agents most commonly used to treat urge incontinence, i.e. anticholinergics, musculotropics and tricyclic antidepressants, are limited in their effectiveness and have anticholinergic adverse effects. Other medications with theoretical treatment potential such as nonsteroidal anti-inflammatory drugs and calcium antagonists require more in depth clinical study before widespread use is appropriate. Although estrogen is well tolerated, its role in the treatment of incontinence in postmenopausal women may be limited. Medical treatment for stress incontinence is most successful in patients with a mild condition. Drugs with alpha-adrenergic activity alone or in combination with estrogen in postmenopausal women, are fairly effective and demonstrate few adverse effects at doses used to treat stress incontinence. Enuresis pharmacotherapy consists mainly of desmopressin and tricyclic antidepressants. Adverse effects are minimal with the doses commonly used. While the majority of patients improve with therapy, a significant portion relapse after treatment is terminated. Tolerability of a particular therapy depends on the effectiveness and adverse effects of the agent, the severity of incontinence and the general health of the patient. In general, patients are willing to accept a greater degree of inconvenience if a drug produces the desired effect. However, individualisation of therapy should be used to maximise compliance and outcome. Blinded, dose-titration studies are needed to better determine doses for optimum tolerability. Research into drugs specifically targeting the lower urinary tract may lead to more effective and well tolerated therapy for incontinence and enuresis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9704249     DOI: 10.2165/00002018-199819020-00004

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  54 in total

1.  The treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double blind placebo controlled study.

Authors:  A J Tapp; L D Cardozo; E Versi; D Cooper
Journal:  Br J Obstet Gynaecol       Date:  1990-06

2.  The standardisation of terminology of lower urinary tract function. The International Continence Society Committee on Standardisation of Terminology.

Authors:  P Abrams; J G Blaivas; S L Stanton; J T Andersen
Journal:  Scand J Urol Nephrol Suppl       Date:  1988

3.  Intravesical instillation of oxybutynin in women with idiopathic detrusor instability: a randomised trial.

Authors:  H Enzelsberger; H Helmer; C Kurz
Journal:  Br J Obstet Gynaecol       Date:  1995-11

4.  Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo.

Authors:  J W Thüroff; B Bunke; A Ebner; P Faber; P de Geeter; J Hannappel; H Heidler; H Madersbacher; H Melchior; W Schäfer
Journal:  J Urol       Date:  1991-04       Impact factor: 7.450

5.  Oral desmopressin as a new treatment modality for primary nocturnal enuresis in adolescents and adults: a double-blind, randomized, multicenter study. Dutch Enuresis Study Group.

Authors:  R A Janknegt; H M Zweers; K P Delaere; A G Kloet; S G Khoe; H J Arendsen
Journal:  J Urol       Date:  1997-02       Impact factor: 7.450

Review 6.  Doxepin up-to-date: a review of its pharmacological properties and therapeutic efficacy with particular reference to depression.

Authors:  R M Pinder; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1977-03       Impact factor: 9.546

Review 7.  Side effects and complications of treatment with desmopressin for enuresis.

Authors:  W L Robson; A K Leung
Journal:  J Natl Med Assoc       Date:  1994-10       Impact factor: 1.798

8.  Double-blind study of imipramine and placebo for incontinence due to bladder instability.

Authors:  C M Castleden; H M Duffin; R S Gulati
Journal:  Age Ageing       Date:  1986-09       Impact factor: 10.668

Review 9.  Drug therapy for nocturnal enuresis. Current treatment recommendations.

Authors:  K Miller; B Atkin; M L Moody
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

10.  Doxepin in the treatment of female detrusor overactivity: a randomized double-blind crossover study.

Authors:  G Lose; L Jørgensen; P Thunedborg
Journal:  J Urol       Date:  1989-10       Impact factor: 7.450

View more
  2 in total

1.  Functional characterization of rat submaxillary gland muscarinic receptors using microphysiometry.

Authors:  T D Meloy; D V Daniels; S S Hegde; R M Eglen; A P Ford
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

Review 2.  Drug-induced urinary retention: incidence, management and prevention.

Authors:  Katia M C Verhamme; Miriam C J M Sturkenboom; Bruno H Ch Stricker; Ruud Bosch
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.